JP7776492B2 - 心筋損傷の処置または防止に使用するためのペプチド - Google Patents

心筋損傷の処置または防止に使用するためのペプチド

Info

Publication number
JP7776492B2
JP7776492B2 JP2023509394A JP2023509394A JP7776492B2 JP 7776492 B2 JP7776492 B2 JP 7776492B2 JP 2023509394 A JP2023509394 A JP 2023509394A JP 2023509394 A JP2023509394 A JP 2023509394A JP 7776492 B2 JP7776492 B2 JP 7776492B2
Authority
JP
Japan
Prior art keywords
peptide
aid
tat
subject
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023509394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537934A (ja
JP2023537934A5 (https=
Inventor
リビア フール，
Original Assignee
ジ ユニバーシティ オブ ウェスタン オーストラリア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902986A external-priority patent/AU2020902986A0/en
Application filed by ジ ユニバーシティ オブ ウェスタン オーストラリア filed Critical ジ ユニバーシティ オブ ウェスタン オーストラリア
Publication of JP2023537934A publication Critical patent/JP2023537934A/ja
Publication of JP2023537934A5 publication Critical patent/JP2023537934A5/ja
Application granted granted Critical
Publication of JP7776492B2 publication Critical patent/JP7776492B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
JP2023509394A 2020-08-21 2021-08-20 心筋損傷の処置または防止に使用するためのペプチド Active JP7776492B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902986A AU2020902986A0 (en) 2020-08-21 Peptides for Use in the Treatment or Prevention of Myocardial Damage
AU2020902986 2020-08-21
PCT/AU2021/050928 WO2022036411A1 (en) 2020-08-21 2021-08-20 Peptides for use in the treatment or prevention of myocardial damage

Publications (3)

Publication Number Publication Date
JP2023537934A JP2023537934A (ja) 2023-09-06
JP2023537934A5 JP2023537934A5 (https=) 2024-08-22
JP7776492B2 true JP7776492B2 (ja) 2025-11-26

Family

ID=80322294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509394A Active JP7776492B2 (ja) 2020-08-21 2021-08-20 心筋損傷の処置または防止に使用するためのペプチド

Country Status (8)

Country Link
US (1) US20240158447A1 (https=)
EP (1) EP4200314A4 (https=)
JP (1) JP7776492B2 (https=)
KR (1) KR20230054440A (https=)
CN (1) CN116615438A (https=)
AU (1) AU2021327085A1 (https=)
CA (1) CA3189838A1 (https=)
WO (1) WO2022036411A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113060A1 (en) 2012-01-31 2013-08-08 The University Of Western Australia Peptide
US20190250145A1 (en) 2017-12-22 2019-08-15 The Trustees Of Columbia University In The City Of New York Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491523B2 (en) * 2004-05-11 2009-02-17 Hirsch Joel A Voltage-dependent calcium channel beta subunit functional core
EP2173372B1 (en) * 2007-06-18 2014-11-19 Agency for Science, Technology and Research Novel peptides and protein and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113060A1 (en) 2012-01-31 2013-08-08 The University Of Western Australia Peptide
US20190250145A1 (en) 2017-12-22 2019-08-15 The Trustees Of Columbia University In The City Of New York Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Dafi, O. et al.，"Negatively charged residues in the N-terminal of the AID helix confer slow voltage dependent inactivation gating to CaV1.2"，Biophys J.，2004年，Vol. 87，pp. 3181-3192
Van Petegem, P. et al.，"Alanine-scanning mutagenesis defines a conserved energetic hotspot in the CaValpha1 AID-CaVbeta interaction site that is critical for channel modulation"，Structure，2008年，Vol. 16，pp. 280-294
Viola, H. M. et al.，"Decreased myocardial injury and improved contractility after administration of a peptide derived against the alpha-interacting domain of the L-type calcium channel"，J. Am. Heart Assoc.，2014年，Vol. 3; e000961，pp. 1-15

Also Published As

Publication number Publication date
KR20230054440A (ko) 2023-04-24
WO2022036411A9 (en) 2025-10-02
AU2021327085A1 (en) 2023-03-02
JP2023537934A (ja) 2023-09-06
EP4200314A4 (en) 2025-01-01
CA3189838A1 (en) 2022-02-24
CN116615438A (zh) 2023-08-18
EP4200314A1 (en) 2023-06-28
US20240158447A1 (en) 2024-05-16
WO2022036411A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
CN104147591B (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
JP6203215B2 (ja) プロミニン−１ペプチド断片およびその使用
JP2020055866A (ja) 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
US20250001014A1 (en) Bag3 compositions and methods
US7910567B2 (en) Opticin nucleic acid administration reduces blood vessel formation
KR20230141958A (ko) 개선된 치료 지수를 위한 플라스민-내성 펩티드
US8409826B2 (en) TAT-utrophin as a protein therapy for dystrophinopathies
US10058588B2 (en) Inhibitors of BCL-2
US7408028B2 (en) Peptides, antibodies thereto, and their use in treatment of central nervous system, damage
JP7776492B2 (ja) 心筋損傷の処置または防止に使用するためのペプチド
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
AU2001259453A1 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
WO2001085981A2 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
US20190112338A1 (en) Decoy Peptides Inhibiting Protein Phosphatase 1-Medicated Dephosphorylation of Phospholamban
WO2020112565A1 (en) Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure
WO2013113060A1 (en) Peptide
JP5870369B2 (ja) 血液脳関門障害改善剤
WO2006075172A2 (en) Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
Belanto A Biochemical and Molecular Analysis of Functional Differences between Dystrophin and Utrophin
BR112015020143B1 (pt) Composição tópica farmacêutica no tratamento ocular tópico e/ou na prevenção de doenças neurodegenerativas da retina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251113

R150 Certificate of patent or registration of utility model

Ref document number: 7776492

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150